NO20052912D0 - Metode for fremstilling av krystallinske former for optiske enantiomerer av modafinil - Google Patents

Metode for fremstilling av krystallinske former for optiske enantiomerer av modafinil

Info

Publication number: NO20052912D0
Authority: NO; Norway
Prior art keywords: enantiomer; ray diffraction; diffraction pattern; interplanar spacings; maxima corresponding
Prior art date: 2002-12-20

Application number

NO20052912A

Other languages

English (en)

Other versions

NO20052912L (no

NO335724B1 (no

Inventor

Gerard Coquerel

Adriaan Jan Van Langevelde

Laurent Courvoisier

Stephanie Graf

Gilles Serrure

Olivier Neckerbrock

Sebastien Rose

Christine Besselievre

Original Assignee

Organisation De Synthese Monof

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-20

Filing date

2005-06-15

Publication date

2005-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32406320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052912(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-06-15 Application filed by Organisation De Synthese Monof filed Critical Organisation De Synthese Monof

2005-06-15 Publication of NO20052912D0 publication Critical patent/NO20052912D0/no

2005-07-19 Publication of NO20052912L publication Critical patent/NO20052912L/no

2015-02-02 Publication of NO335724B1 publication Critical patent/NO335724B1/no

Links

HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 title abstract 4
YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 title abstract 2
238000000034 method Methods 0.000 title abstract 2
229960001165 modafinil Drugs 0.000 title abstract 2
230000003287 optical effect Effects 0.000 title 1
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 abstract 9
239000012453 solvate Substances 0.000 abstract 6
238000002441 X-ray diffraction Methods 0.000 abstract 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
230000001777 nootropic effect Effects 0.000 abstract 2
238000002360 preparation method Methods 0.000 abstract 2
239000002904 solvent Substances 0.000 abstract 2
125000005907 alkyl ester group Chemical group 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
150000001408 amides Chemical class 0.000 abstract 1
230000001430 anti-depressive effect Effects 0.000 abstract 1
230000000648 anti-parkinson Effects 0.000 abstract 1
239000000935 antidepressant agent Substances 0.000 abstract 1
229940005513 antidepressants Drugs 0.000 abstract 1
239000000939 antiparkinson agent Substances 0.000 abstract 1
230000001966 cerebroprotective effect Effects 0.000 abstract 1
238000002425 crystallisation Methods 0.000 abstract 1
230000008025 crystallization Effects 0.000 abstract 1
IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000000463 material Substances 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
QARQPIWTMBRJFX-UHFFFAOYSA-N modafinil acid Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)O)C1=CC=CC=C1 QARQPIWTMBRJFX-UHFFFAOYSA-N 0.000 abstract 1
239000003176 neuroleptic agent Substances 0.000 abstract 1
230000000701 neuroleptic effect Effects 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1
150000007530 organic bases Chemical class 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229940125725 tranquilizer Drugs 0.000 abstract 1
239000003204 tranquilizing agent Substances 0.000 abstract 1
230000002936 tranquilizing effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/06—Separation; Purification; Stabilisation; Use of additives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Nutrition Science (AREA)
Psychology (AREA)
Child & Adolescent Psychology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Anesthesiology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20052912A 2002-12-20 2005-06-15 Krystallinske former av optiske enantiomerer av modafinil, farmasøytiske blandinger omfattende slike, fremgangsmåte for fremstilling av slike samt deres anvendelse NO335724B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0216412A FR2849029B1 (fr)	2002-12-20	2002-12-20	Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
PCT/FR2003/003799 WO2004060858A1 (fr)	2002-12-20	2003-12-18	Procede de preparation et formes cristallines des enantiomeres optiques du modafinil

Publications (3)

Publication Number	Publication Date
NO20052912D0 true NO20052912D0 (no)	2005-06-15
NO20052912L NO20052912L (no)	2005-07-19
NO335724B1 NO335724B1 (no)	2015-02-02

Family

ID=32406320

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20052912A NO335724B1 (no)	2002-12-20	2005-06-15	Krystallinske former av optiske enantiomerer av modafinil, farmasøytiske blandinger omfattende slike, fremgangsmåte for fremstilling av slike samt deres anvendelse

Country Status (30)

Country	Link
US (10)	US7132570B2 (no)
EP (6)	EP2679578B1 (no)
JP (2)	JP4719471B2 (no)
KR (1)	KR101050565B1 (no)
CN (5)	CN101012189B (no)
AR (1)	AR042546A1 (no)
AU (2)	AU2003299349C1 (no)
BR (1)	BRPI0316916B1 (no)
CA (2)	CA2510096C (no)
CL (2)	CL2007002450A1 (no)
CY (1)	CY1114291T1 (no)
DK (1)	DK2343275T3 (no)
EA (1)	EA009592B1 (no)
EG (1)	EG24849A (no)
ES (3)	ES2575018T3 (no)
FR (1)	FR2849029B1 (no)
HK (1)	HK1225371A1 (no)
IL (1)	IL169205A (no)
IS (1)	IS7947A (no)
MX (1)	MXPA05006525A (no)
MY (1)	MY142926A (no)
NO (1)	NO335724B1 (no)
NZ (2)	NZ540733A (no)
PL (1)	PL377196A1 (no)
PT (1)	PT2343275E (no)
SI (1)	SI2343275T1 (no)
TW (1)	TWI344952B (no)
UA (1)	UA100964C2 (no)
WO (1)	WO2004060858A1 (no)
ZA (1)	ZA200504805B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7927613B2 (en)	2002-02-15	2011-04-19	University Of South Florida	Pharmaceutical co-crystal compositions
WO2004000284A1 (en)	2002-06-21	2003-12-31	Transform Pharmaceuticals, Inc.	Pharmaceutical compositions with improved dissolution
US7790905B2 (en)	2002-02-15	2010-09-07	Mcneil-Ppc, Inc.	Pharmaceutical propylene glycol solvate compositions
CA2477923C (en)	2002-03-01	2021-02-23	University Of South Florida	Multiple-component solid phases containing at least one active pharmaceutical ingredient
FR2849029B1 (fr)	2002-12-20	2005-03-18	Lafon Labor	Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
US8183290B2 (en)	2002-12-30	2012-05-22	Mcneil-Ppc, Inc.	Pharmaceutically acceptable propylene glycol solvate of naproxen
EP1603889A1 (en) *	2003-03-17	2005-12-14	Hetero Drugs Limited	Novel crystalline forms of lamotrigine
CA2519117C (en) *	2003-03-17	2010-03-02	Neurohealing Pharmaceuticals, Inc.	High potency dopaminergic treatment of neurological impairment associated with brain injury
JP4842819B2 (ja) *	2003-09-04	2011-12-21	セフアロン・インコーポレーテツド	モダフィニル組成物
US7368591B2 (en)	2003-09-19	2008-05-06	Cephalon France	Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
EP1516869A1 (en)	2003-09-19	2005-03-23	Cephalon France	Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US20090018202A1 (en) *	2004-02-06	2009-01-15	Cephalon, Inc.	Modafinil compositions
EP2292213A1 (en) *	2004-02-06	2011-03-09	Cephalon, Inc.	Compositions comprising a polymorphic form of armodafinil
CA2556106A1 (en) *	2004-02-06	2005-08-25	Cephalon, Inc.	Modafinil compositions
CA2701710C (en)	2004-07-20	2013-08-27	Warner-Lambert Company Llc	Novel forms of [r-(r,r)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US20060086667A1 (en) *	2004-09-13	2006-04-27	Cephalon, Inc., U.S. Corporation	Methods for the separation of enantiomeric sulfinylacetamides
EP1702915A1 (en) *	2005-03-14	2006-09-20	Cephalon France	Process for enantioselective synthesis of single enantiomers of thio-substituted arylmethanesulfinyl derivatives by asymmetric oxidation
CA2614777C (en) *	2005-07-21	2012-04-17	Neurohealing Pharmaceuticals, Inc.	Rapid onset and short term modafinil compositions and methods of use thereof
US20070293702A1 (en) *	2006-02-21	2007-12-20	Viviana Braude	Novel crystalline forms of armodafinil and preparation thereof
WO2007103221A2 (en) *	2006-03-01	2007-09-13	Teva Pharmaceutical Industries Ltd.	An improved process for the preparation of armodafinil
KR20090031618A (ko) *	2006-07-12	2009-03-26	엘란 코포레이션, 피엘씨	나노입자형 모다피닐 제제
EP2056811B8 (en) *	2006-08-14	2018-03-21	Neurohealing Pharmaceuticals, Inc.	Modafinil-based treatment for premature ejaculation
WO2008070143A1 (en) *	2006-12-06	2008-06-12	Teva Pharmaceutical Industries Ltd.	Processes for preparing armodafinil intermediate
CN101641090B (zh) *	2006-12-19	2012-12-05	亚勒斯有限公司	莫达非尼在制备治疗多动腿综合征的药物中的应用
US20100234468A1 (en) *	2007-06-04	2010-09-16	Abhay Gaitonde	Novel process
WO2009024863A2 (en) *	2007-06-26	2009-02-26	Actavis Group Ptc Ehf	Process for the preparation of modafinil enantiomers
WO2009025791A2 (en) *	2007-08-16	2009-02-26	Teva Pharmaceutical Industries Ltd.	Purification of armodafinil
US20090082462A1 (en) *	2007-09-25	2009-03-26	Protia, Llc	Deuterium-enriched armodafinil
US20090105346A1 (en) *	2007-10-02	2009-04-23	Alexandr Jegorov	Novel crystalline forms of armodafinil and preparation thereof
WO2009090663A1 (en) *	2008-01-15	2009-07-23	Lupin Limited	Novel crystalline polymorph of armodafinil and an improved process for preparation thereof
US20090325999A1 (en) *	2008-06-27	2009-12-31	Jie Du	Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
US20100036164A1 (en) *	2008-08-06	2010-02-11	Srinivas Areveli	Preparation of armodafinil form i
EP2292306B1 (en)	2009-09-02	2013-05-01	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Method for separation of racemic compound-forming chiral substances by a cyclic crystallization process and a crystallization device
WO2011061610A2 (en) *	2009-11-19	2011-05-26	Ranbaxy Laboratories Limited	Processes for preparation of polymorphic forms of lacosamide
MX2012007813A (es) *	2010-01-07	2012-08-01	Vivus Inc	Tratamiento del sindrome de apnea obstructiva del sueño con una combinacion de un hinibidor de anhidrasa carbonica y un agente activo adicional.
HUE037616T2 (hu)	2010-12-08	2018-09-28	Codexis Inc	Biokatalizátorok és eljárások armodafinil szintéziséhez
JP6116847B2 (ja) *	2012-10-01	2017-04-19	アムビトバイオサイエンシスコーポレーションＡｍｂｉｔＢｉｏｓｃｉｅｎｃｅｓＣｏｒｐｏｒａｔｉｏｎ	シクロデキストリンとの混合体を含有する錠剤
US10466776B2 (en) *	2014-06-24	2019-11-05	Paypal, Inc.	Surfacing related content based on user interaction with currently presented content
WO2016012865A2 (en) *	2014-07-23	2016-01-28	Yonatan Wexler	Wearable apparatus and methods for processing image data
KR20180123194A (ko) *	2014-11-27	2018-11-14	가부시키가이샤 지씨	왁스 패턴용 표면처리제 및 치과용 보철물을 제조하기 위한 방법
WO2017064723A1 (en) *	2015-10-12	2017-04-20	Natco Pharma Ltd	An improved process for the preparation of armodafinil

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1905990A (en)	1931-01-02	1933-04-25	Hoffmann La Roche	Disubstituted carbamic acid esters of phenols containing a basic constituent
GB1197809A (en)	1968-02-13	1970-07-08	Inst Noguchi	Method for Continuous Optical Resolution of Organic Racemates.
GB1584462A (en)	1977-03-31	1981-02-11	Lafon Labor	N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2593809B1 (fr)	1986-01-31	1988-07-22	Lafon Labor	Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2597864B1 (fr)	1986-04-28	1990-11-16	Lafon Labor	Nouveaux derives de la n-((trimethoxy-2,4,6-benzoyl)-3 propyl) piperidine, leurs procedes de preparation et leur application en therapeutique
FR2626881B1 (fr)	1988-02-10	1990-07-27	Lafon Labor	1-(4-aminophenyl)-2-hexamethyleneiminopropanone, procede de preparation et utilisation en therapeutique
FR2663225B1 (fr) *	1990-06-14	1994-11-04	Lafon Labor	Nouvelle utilisation du modafinil.
FR2671349B1 (fr)	1991-01-09	1993-04-23	Lafon Labor	Nouveaux derives de 1,4-dihydropyridine, leur procede de preparation et composition therapeutique les contenant.
FR2710337B1 (fr) *	1993-09-23	1995-12-08	Gerard Coquerel	Procédé de dédoublement de deux antipodes optiques par entraînement polythermique programmé et autoensemencé.
US6894171B1 (en)	1998-07-20	2005-05-17	Abbott Laboratories	Polymorph of a pharmaceutical
CN1249932A (zh)	1999-09-29	2000-04-12	付俊昌	一种莫达芬尼及其光学对映体l及d异构体的新用途
WO2001051919A2 (en)	2000-01-07	2001-07-19	Transform Pharmaceuticals, Inc.	High-throughput formation, identification, and analysis of diverse solid-forms
US20010036640A1 (en)	2000-04-25	2001-11-01	D'amico Kevin L.	System and methods for the high throughput screening of polymorphs
US6492396B2 (en) *	2000-05-16	2002-12-10	Cephalon, Inc.	Substituted thioacetamides
US6670358B2 (en)	2000-05-16	2003-12-30	Cephalon, Inc.	Substituted thioacetamides
DE10025756C2 (de) *	2000-05-25	2003-02-20	Cognis Deutschland Gmbh	Lösungsvermittler
CZ2003529A3 (cs) *	2000-07-27	2003-09-17	Teva Pharmaceutical Industries Ltd.	Krystalický a čistý modafinil a postup jeho přípravy
US6835307B2 (en) *	2000-08-04	2004-12-28	Battelle Memorial Institute	Thermal water treatment
US6489363B2 (en)	2000-10-11	2002-12-03	Cephalon, Inc.	Pharmaceutical solutions of modafinil compounds
US6919378B2 (en)	2000-10-11	2005-07-19	Cephalon, Inc.	Pharmaceutical solutions of modafinil compounds
EP1332130A4 (en)	2000-11-03	2004-01-21	Teva Pharma	HEMICALCIC ATORVASTATIN FORM VII
ATE357228T1 (de)	2001-05-25	2007-04-15	Cephalon Inc	Feste pharmazeutische formulierung enthaltend modafinil
US20030124028A1 (en)	2001-08-10	2003-07-03	Carlson Eric D.	Apparatuses and methods for creating and testing pre-formulations and systems for same
EP1466166B2 (en)	2002-01-15	2013-05-01	Avantium International B.V.	Method for performing powder diffraction analysis
US6875893B2 (en) *	2002-05-23	2005-04-05	Cephalon, Inc.	Preparations of a sulfinyl acetamide
US7229644B2 (en)	2002-05-23	2007-06-12	Cephalon, Inc.	Pharmaceutical formulations of modafinil
US20040048931A1 (en)	2002-07-12	2004-03-11	Craig Heacock	Modafinil pharmaceutical compositions
ATE366137T1 (de)	2002-08-02	2007-07-15	Avantium Int Bv	Vorrichtung und verfahren zur parallelen durchführung chemischer experimente, insbesondere kristallisationsexperimente
US6992219B2 (en)	2002-08-09	2006-01-31	Cephalon France	Modafinil polymorphic forms
EP1567497B1 (en)	2002-12-06	2009-09-23	Purdue Research Foundation	Pyridines for treating injured mammalian nerve tissue
FR2849029B1 (fr)	2002-12-20	2005-03-18	Lafon Labor	Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
US7566805B2 (en) *	2003-09-04	2009-07-28	Cephalon, Inc.	Modafinil compositions
MXPA06002507A (es)	2003-09-04	2006-06-20	Cephalon Inc	Composiciones de modafinil.
US20090018202A1 (en) *	2004-02-06	2009-01-15	Cephalon, Inc.	Modafinil compositions
CA2556106A1 (en)	2004-02-06	2005-08-25	Cephalon, Inc.	Modafinil compositions
EP2708531A1 (en)	2004-10-13	2014-03-19	Pharmacia & Upjohn Company LLC	Crystalline Forms Of 3-[5-Chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide
CA2614777C (en) *	2005-07-21	2012-04-17	Neurohealing Pharmaceuticals, Inc.	Rapid onset and short term modafinil compositions and methods of use thereof
US20070293702A1 (en) *	2006-02-21	2007-12-20	Viviana Braude	Novel crystalline forms of armodafinil and preparation thereof
WO2007103221A2 (en)	2006-03-01	2007-09-13	Teva Pharmaceutical Industries Ltd.	An improved process for the preparation of armodafinil
US20100234468A1 (en)	2007-06-04	2010-09-16	Abhay Gaitonde	Novel process
WO2009024863A2 (en)	2007-06-26	2009-02-26	Actavis Group Ptc Ehf	Process for the preparation of modafinil enantiomers
WO2009025791A2 (en)	2007-08-16	2009-02-26	Teva Pharmaceutical Industries Ltd.	Purification of armodafinil
US20090105346A1 (en) *	2007-10-02	2009-04-23	Alexandr Jegorov	Novel crystalline forms of armodafinil and preparation thereof
EP1911739A3 (en) *	2007-11-05	2008-09-17	Dipharma Francis S.r.l.	Crystalline form of (S)-2-phenylethylammonium (R)-diphenyl-methanesulphinyl-acetate
WO2009090663A1 (en)	2008-01-15	2009-07-23	Lupin Limited	Novel crystalline polymorph of armodafinil and an improved process for preparation thereof

2002
- 2002-12-20 FR FR0216412A patent/FR2849029B1/fr not_active Expired - Fee Related
2003
- 2003-12-18 ES ES13177660.1T patent/ES2575018T3/es not_active Expired - Lifetime
- 2003-12-18 EA EA200501016A patent/EA009592B1/ru not_active IP Right Cessation
- 2003-12-18 WO PCT/FR2003/003799 patent/WO2004060858A1/fr not_active Ceased
- 2003-12-18 DK DK11163602.3T patent/DK2343275T3/da active
- 2003-12-18 CN CN2007100017638A patent/CN101012189B/zh not_active Expired - Fee Related
- 2003-12-18 NZ NZ540733A patent/NZ540733A/en not_active IP Right Cessation
- 2003-12-18 SI SI200332281T patent/SI2343275T1/sl unknown
- 2003-12-18 ES ES11163602T patent/ES2425023T3/es not_active Expired - Lifetime
- 2003-12-18 AU AU2003299349A patent/AU2003299349C1/en active Active
- 2003-12-18 MX MXPA05006525A patent/MXPA05006525A/es active IP Right Grant
- 2003-12-18 EP EP13177660.1A patent/EP2679578B1/fr not_active Expired - Lifetime
- 2003-12-18 EP EP13177661.9A patent/EP2676952A3/fr not_active Withdrawn
- 2003-12-18 CN CN2010101503175A patent/CN101914044A/zh active Pending
- 2003-12-18 PL PL377196A patent/PL377196A1/pl unknown
- 2003-12-18 CA CA2510096A patent/CA2510096C/fr not_active Expired - Lifetime
- 2003-12-18 CN CN201610461501.9A patent/CN106065007A/zh active Pending
- 2003-12-18 US US10/539,918 patent/US7132570B2/en not_active Expired - Fee Related
- 2003-12-18 KR KR1020057011619A patent/KR101050565B1/ko not_active Expired - Lifetime
- 2003-12-18 NZ NZ571235A patent/NZ571235A/en not_active IP Right Cessation
- 2003-12-18 UA UAA200507106A patent/UA100964C2/ru unknown
- 2003-12-18 EP EP03799631.1A patent/EP1572635B1/fr not_active Expired - Lifetime
- 2003-12-18 CN CNB2003801098134A patent/CN100540533C/zh not_active Expired - Fee Related
- 2003-12-18 ES ES03799631.1T patent/ES2627808T3/es not_active Expired - Lifetime
- 2003-12-18 EP EP11163602.3A patent/EP2343275B1/fr not_active Expired - Lifetime
- 2003-12-18 BR BRPI0316916-2A patent/BRPI0316916B1/pt not_active IP Right Cessation
- 2003-12-18 PT PT111636023T patent/PT2343275E/pt unknown
- 2003-12-18 EP EP13177658.5A patent/EP2679577A3/fr not_active Withdrawn
- 2003-12-18 EP EP13177648.6A patent/EP2679576A3/fr not_active Withdrawn
- 2003-12-18 CA CA2724305A patent/CA2724305A1/fr not_active Abandoned
- 2003-12-18 JP JP2004564285A patent/JP4719471B2/ja not_active Expired - Fee Related
- 2003-12-18 CN CN200910152177A patent/CN101654423A/zh active Pending
- 2003-12-19 AR ARP030104730A patent/AR042546A1/es not_active Application Discontinuation
- 2003-12-22 TW TW092136443A patent/TWI344952B/zh not_active IP Right Cessation
- 2003-12-22 MY MYPI20034935A patent/MY142926A/en unknown
2005
- 2005-06-13 ZA ZA200504805A patent/ZA200504805B/en unknown
- 2005-06-15 NO NO20052912A patent/NO335724B1/no not_active IP Right Cessation
- 2005-06-16 IL IL169205A patent/IL169205A/en active IP Right Grant
- 2005-06-19 EG EGNA2005000326 patent/EG24849A/xx active
- 2005-07-19 IS IS7947A patent/IS7947A/is unknown
2006
- 2006-06-26 US US11/474,859 patent/US20060241320A1/en not_active Abandoned
2007
- 2007-08-22 CL CL2007002450A patent/CL2007002450A1/es unknown
2009
- 2009-07-22 US US12/507,631 patent/US20100048720A1/en not_active Abandoned
- 2009-07-22 US US12/507,610 patent/US20100048719A1/en not_active Abandoned
- 2009-07-22 US US12/507,584 patent/US9382200B2/en not_active Expired - Fee Related
- 2009-07-22 US US12/507,602 patent/US20100048718A1/en not_active Abandoned
- 2009-07-22 US US12/507,594 patent/US20090281192A1/en not_active Abandoned
- 2009-07-22 US US12/507,623 patent/US20090281193A1/en not_active Abandoned
2010
- 2010-08-20 AU AU2010212462A patent/AU2010212462A1/en not_active Abandoned
2011
- 2011-02-17 JP JP2011032155A patent/JP5497680B2/ja not_active Expired - Lifetime
2013
- 2013-04-08 US US13/858,483 patent/US8729305B2/en not_active Expired - Fee Related
- 2013-07-08 CY CY20131100573T patent/CY1114291T1/el unknown
- 2013-08-28 US US14/012,363 patent/US8975442B2/en not_active Expired - Fee Related
2016
- 2016-10-17 CL CL2016002640A patent/CL2016002640A1/es unknown
- 2016-12-01 HK HK16113750.5A patent/HK1225371A1/zh unknown

Also Published As

Publication number	Publication date
EP2679577A3 (fr)	2014-02-12
EP1572635B1 (fr)	2017-04-12
EP2679578B1 (fr)	2016-03-09
EP2343275A2 (fr)	2011-07-13
NO20052912L (no)	2005-07-19
HK1192222A1 (zh)	2014-08-15
EG24849A (en)	2010-10-27
CA2510096C (fr)	2011-02-22
US20130274521A1 (en)	2013-10-17
UA100964C2 (ru)	2013-02-25
PL377196A1 (pl)	2006-01-23
ES2425023T3 (es)	2013-10-10
KR20050085847A (ko)	2005-08-29
CY1114291T1 (el)	2016-08-31
CN100540533C (zh)	2009-09-16
EP2679576A3 (fr)	2014-02-12
TWI344952B (en)	2011-07-11
CA2724305A1 (fr)	2004-07-22
US7132570B2 (en)	2006-11-07
AR042546A1 (es)	2005-06-22
AU2003299349A8 (en)	2004-07-29
AU2003299349B2 (en)	2010-06-03
NZ571235A (en)	2010-01-29
CN106065007A (zh)	2016-11-02
EP2343275B1 (fr)	2013-04-24
EP2343275A3 (fr)	2011-08-17
ZA200504805B (en)	2006-07-26
PT2343275E (pt)	2013-07-30
CL2016002640A1 (es)	2017-03-24
AU2003299349C1 (en)	2011-01-20
FR2849029B1 (fr)	2005-03-18
JP4719471B2 (ja)	2011-07-06
BR0316916A (pt)	2005-10-18
NO335724B1 (no)	2015-02-02
TW200419175A (en)	2004-10-01
CN101012189B (zh)	2013-03-13
EP2676952A2 (fr)	2013-12-25
SI2343275T1 (sl)	2013-10-30
JP2011102330A (ja)	2011-05-26
JP5497680B2 (ja)	2014-05-21
US20060135621A1 (en)	2006-06-22
AU2010212462A1 (en)	2010-09-16
US20100022653A1 (en)	2010-01-28
EP2679576A2 (fr)	2014-01-01
EP1572635A1 (fr)	2005-09-14
US20140031589A1 (en)	2014-01-30
US20100048720A1 (en)	2010-02-25
CL2007002450A1 (es)	2009-01-16
DK2343275T3 (da)	2013-07-01
FR2849029A1 (fr)	2004-06-25
CA2510096A1 (fr)	2004-07-22
ES2627808T3 (es)	2017-07-31
BRPI0316916A8 (pt)	2015-09-22
NZ540733A (en)	2008-10-31
MXPA05006525A (es)	2005-12-05
US20090281193A1 (en)	2009-11-12
US20060241320A1 (en)	2006-10-26
JP2006511588A (ja)	2006-04-06
AU2003299349A1 (en)	2004-07-29
US20100048719A1 (en)	2010-02-25
BRPI0316916B1 (pt)	2021-11-30
EP2679578A3 (fr)	2014-03-19
CN1751021A (zh)	2006-03-22
US8975442B2 (en)	2015-03-10
KR101050565B1 (ko)	2011-07-19
ES2575018T3 (es)	2016-06-23
EA200501016A1 (ru)	2005-12-29
IS7947A (is)	2005-07-19
EP2679577A2 (fr)	2014-01-01
CN101914044A (zh)	2010-12-15
MY142926A (en)	2011-01-31
US20100048718A1 (en)	2010-02-25
HK1225371A1 (zh)	2017-09-08
WO2004060858A1 (fr)	2004-07-22
EA009592B1 (ru)	2008-02-28
CN101012189A (zh)	2007-08-08
US9382200B2 (en)	2016-07-05
US20090281192A1 (en)	2009-11-12
CN101654423A (zh)	2010-02-24
IL169205A (en)	2013-11-28
EP2676952A3 (fr)	2014-02-12
US8729305B2 (en)	2014-05-20
EP2679578A2 (fr)	2014-01-01

Legal Events

Date	Code	Title	Description
2024-01-15	MK1K	Patent expired

Publication	Publication Date	Title
NO20052912D0 (no)	2005-06-15	Metode for fremstilling av krystallinske former for optiske enantiomerer av modafinil
DE60311599T2 (de)	2007-10-25	Verfahren zur herstellung von duloxetin und deren verwendeten zwischenprodukten
SE0103046L (sv)	2001-11-14	Kristallin bas av citalopram
PT100673B (pt)	1999-07-30	Processo para a preparacao de intermediarios de sertralina e compostos assim obtidos
NO170685B (no)	1992-08-10	Optisk aktive alkyl-aryl-ketaler
Kato et al.	1999	Improved synthetic methods of CP-060S, a novel cardioprotective drug
PT768309E (pt)	2003-02-28	Processo para a preparacao de compostos de imidazolilo enantiomericamente puros
KR102236806B1 (ko)	2021-04-06	거울상 이성질체 농후화된 3-아미노피페리딘의 제조 방법
BR0109507A (pt)	2002-12-10	Processo para preparação de forma i, cristalina, de carbegolina
PT759904E (pt)	2000-10-31	Processo e sais diastereomericos uteis para a resolucao optica de alfa-¬4-(1,1-dimetiletil)-fenil\|-4-(hidroxidifenilmetil)-1-piperidinobutanol racemico e compostos derivados
ES2307209T3 (es)	2008-11-16	Procedimiento de produccion de un enantiomero de amlodipina con una pureza optica alta.
Asberom et al.	2007	Tetrahydroquinoline sulfonamides as γ-secretase inhibitors
AR032433A1 (es)	2003-11-12	Proceso para la preparacion de un isomero de anillo de 5 miembros 3-sustituido y compuestos intermediarios utiles en el mismo
AR030938A1 (es)	2003-09-03	Proceso de obtencion de los enantiomeros de la cetamina racemica; proceso de obtencion de sales farmaceuticamente aceptables de enantiomeros de la cetamina racemica y utilizacion de las sales farmaceuticamente aceptables obtenidas por el referido proceso
ES2323742T3 (es)	2009-07-23	Derivados de 4-(aril)(ariloxi)metil piperidina y su uso como inhibidores de la recaptacion de serotonina y/o noradrenalina.
Fang et al.	1999	First preparation of enantiomerically pure sibutramine and its major metabolite, and determination of their absolute configuration by single crystal X-ray analysis
SE8102525L (sv)	1981-10-24	Forfarande for framstellning av cyklopropankarboxylsyraester-derivat
ES2214263T3 (es)	2004-09-16	3-bicicloaril-2-aminometil bicicloalcanos como inhibidores de la recaptacion de serotonina.
ATE402157T1 (de)	2008-08-15	Verfahren zur herstellung von mycophenolatmofetil
CH685345A5 (it)	1995-06-15	Metodo per la preparazione di acido S-(+)-etodolico e di suoi derivati salini.
KR101842425B1 (ko)	2018-05-14	시탈로프람 및 에스시탈로프람의 신규 제조방법
AR012346A1 (es)	2000-10-18	Proceso para la fabricacion de compuestos racemicos, compuestos obtenidos por dicho proceso y compuestos intermediarios
Schjelderup et al.	1986	The absolute configuration of oxyphencyclimine, a parasympatholytic drug. Syntheses of both enantiomers
KR880011096A (ko)	1988-10-26	광학 활성 옥소-이소인돌리닐 유도체
Shi et al.	2006	Racemization of (S)-(+)-10, 11-dimethoxyaporphine and (S)-(+)-aporphine: efficient preparations of (R)-(−)-apomorphine and (R)-(−)-aporphine via a recycle process of resolution